A designer bow-tie combination therapeutic platform: An approach to resistant cancer treatment by simultaneous delivery of cytotoxic and anti-inflammatory agents and radiation

Rakesh K. Pathak, Uttara Basu, Anis Ahmad, Shrita Sarkar, Anil Kumar, Bapurao Surnar, Saba Ansari, Katarzyna Wilczek, Michael E. Ivan, Brian Marples, Nagesh Kolishetti, Shanta Dhar

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Multimodal therapies are used to treat advanced cancers including castration-resistant prostate cancer to manage the biological characteristics of the tumors like inflammation, bone metastases, and participation of metabolically altered cancer stem cells (CSCs) that have integral roles in disease dissemination and progression. We developed a multifunctional polymer-based self-assembled technology to deliver a predefined stoichiometric combination of a chemotherapy and an anti-inflammatory agent in a stimuli responsive manner, to complement and improve the currently established treatment methods of prostate cancer. We combined clinically applicable fractionated radiation therapy (XRT) to further sensitize the activity of this targeted multifunctional platform towards prostate-specific membrane antigen (PSMA) expressing advanced prostate cancer. After irradiation, our PSMA-targeted self-assembly system could modulate the mitochondrial metabolism, cellular respiration and the overall radiation-induced DNA damage process. We report the synthesis of this advanced multifunctional platform and describe its unique properties that allow the ability to load multiple FDA approved drugs with a predefined stoichiometric ratio for targeted co-delivery of chemotherapeutics and anti-inflammatory agents. The efficacy of this platform was demonstrated using several in vitro and in vivo studies, in a unique bilateral PSMA expressing prostate cancer tumor model, and in patient derived CSCs.

Original languageEnglish (US)
Pages (from-to)117-129
Number of pages13
JournalBiomaterials
Volume187
DOIs
StatePublished - Dec 1 2018

Fingerprint

Oncology
Antigens
Prostatic Neoplasms
Anti-Inflammatory Agents
Radiation
Stem cells
Membranes
Neoplastic Stem Cells
Tumors
Neoplasms
Chemotherapy
Radiotherapy
Cell Respiration
Metabolism
Osteitis
Self assembly
Castration
Polymers
Bone
DNA

Keywords

  • Aspirin prodrug
  • Cancer stem cells
  • Cisplatin prodrug
  • Inflammation
  • Mitochondria
  • Radiation therapy
  • Targeted nanoparticles

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

A designer bow-tie combination therapeutic platform : An approach to resistant cancer treatment by simultaneous delivery of cytotoxic and anti-inflammatory agents and radiation. / Pathak, Rakesh K.; Basu, Uttara; Ahmad, Anis; Sarkar, Shrita; Kumar, Anil; Surnar, Bapurao; Ansari, Saba; Wilczek, Katarzyna; Ivan, Michael E.; Marples, Brian; Kolishetti, Nagesh; Dhar, Shanta.

In: Biomaterials, Vol. 187, 01.12.2018, p. 117-129.

Research output: Contribution to journalArticle

Pathak, Rakesh K. ; Basu, Uttara ; Ahmad, Anis ; Sarkar, Shrita ; Kumar, Anil ; Surnar, Bapurao ; Ansari, Saba ; Wilczek, Katarzyna ; Ivan, Michael E. ; Marples, Brian ; Kolishetti, Nagesh ; Dhar, Shanta. / A designer bow-tie combination therapeutic platform : An approach to resistant cancer treatment by simultaneous delivery of cytotoxic and anti-inflammatory agents and radiation. In: Biomaterials. 2018 ; Vol. 187. pp. 117-129.
@article{b6b21160a4a045a7a387bd2076cdbfe7,
title = "A designer bow-tie combination therapeutic platform: An approach to resistant cancer treatment by simultaneous delivery of cytotoxic and anti-inflammatory agents and radiation",
abstract = "Multimodal therapies are used to treat advanced cancers including castration-resistant prostate cancer to manage the biological characteristics of the tumors like inflammation, bone metastases, and participation of metabolically altered cancer stem cells (CSCs) that have integral roles in disease dissemination and progression. We developed a multifunctional polymer-based self-assembled technology to deliver a predefined stoichiometric combination of a chemotherapy and an anti-inflammatory agent in a stimuli responsive manner, to complement and improve the currently established treatment methods of prostate cancer. We combined clinically applicable fractionated radiation therapy (XRT) to further sensitize the activity of this targeted multifunctional platform towards prostate-specific membrane antigen (PSMA) expressing advanced prostate cancer. After irradiation, our PSMA-targeted self-assembly system could modulate the mitochondrial metabolism, cellular respiration and the overall radiation-induced DNA damage process. We report the synthesis of this advanced multifunctional platform and describe its unique properties that allow the ability to load multiple FDA approved drugs with a predefined stoichiometric ratio for targeted co-delivery of chemotherapeutics and anti-inflammatory agents. The efficacy of this platform was demonstrated using several in vitro and in vivo studies, in a unique bilateral PSMA expressing prostate cancer tumor model, and in patient derived CSCs.",
keywords = "Aspirin prodrug, Cancer stem cells, Cisplatin prodrug, Inflammation, Mitochondria, Radiation therapy, Targeted nanoparticles",
author = "Pathak, {Rakesh K.} and Uttara Basu and Anis Ahmad and Shrita Sarkar and Anil Kumar and Bapurao Surnar and Saba Ansari and Katarzyna Wilczek and Ivan, {Michael E.} and Brian Marples and Nagesh Kolishetti and Shanta Dhar",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.biomaterials.2018.08.062",
language = "English (US)",
volume = "187",
pages = "117--129",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - A designer bow-tie combination therapeutic platform

T2 - An approach to resistant cancer treatment by simultaneous delivery of cytotoxic and anti-inflammatory agents and radiation

AU - Pathak, Rakesh K.

AU - Basu, Uttara

AU - Ahmad, Anis

AU - Sarkar, Shrita

AU - Kumar, Anil

AU - Surnar, Bapurao

AU - Ansari, Saba

AU - Wilczek, Katarzyna

AU - Ivan, Michael E.

AU - Marples, Brian

AU - Kolishetti, Nagesh

AU - Dhar, Shanta

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Multimodal therapies are used to treat advanced cancers including castration-resistant prostate cancer to manage the biological characteristics of the tumors like inflammation, bone metastases, and participation of metabolically altered cancer stem cells (CSCs) that have integral roles in disease dissemination and progression. We developed a multifunctional polymer-based self-assembled technology to deliver a predefined stoichiometric combination of a chemotherapy and an anti-inflammatory agent in a stimuli responsive manner, to complement and improve the currently established treatment methods of prostate cancer. We combined clinically applicable fractionated radiation therapy (XRT) to further sensitize the activity of this targeted multifunctional platform towards prostate-specific membrane antigen (PSMA) expressing advanced prostate cancer. After irradiation, our PSMA-targeted self-assembly system could modulate the mitochondrial metabolism, cellular respiration and the overall radiation-induced DNA damage process. We report the synthesis of this advanced multifunctional platform and describe its unique properties that allow the ability to load multiple FDA approved drugs with a predefined stoichiometric ratio for targeted co-delivery of chemotherapeutics and anti-inflammatory agents. The efficacy of this platform was demonstrated using several in vitro and in vivo studies, in a unique bilateral PSMA expressing prostate cancer tumor model, and in patient derived CSCs.

AB - Multimodal therapies are used to treat advanced cancers including castration-resistant prostate cancer to manage the biological characteristics of the tumors like inflammation, bone metastases, and participation of metabolically altered cancer stem cells (CSCs) that have integral roles in disease dissemination and progression. We developed a multifunctional polymer-based self-assembled technology to deliver a predefined stoichiometric combination of a chemotherapy and an anti-inflammatory agent in a stimuli responsive manner, to complement and improve the currently established treatment methods of prostate cancer. We combined clinically applicable fractionated radiation therapy (XRT) to further sensitize the activity of this targeted multifunctional platform towards prostate-specific membrane antigen (PSMA) expressing advanced prostate cancer. After irradiation, our PSMA-targeted self-assembly system could modulate the mitochondrial metabolism, cellular respiration and the overall radiation-induced DNA damage process. We report the synthesis of this advanced multifunctional platform and describe its unique properties that allow the ability to load multiple FDA approved drugs with a predefined stoichiometric ratio for targeted co-delivery of chemotherapeutics and anti-inflammatory agents. The efficacy of this platform was demonstrated using several in vitro and in vivo studies, in a unique bilateral PSMA expressing prostate cancer tumor model, and in patient derived CSCs.

KW - Aspirin prodrug

KW - Cancer stem cells

KW - Cisplatin prodrug

KW - Inflammation

KW - Mitochondria

KW - Radiation therapy

KW - Targeted nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85054816743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054816743&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2018.08.062

DO - 10.1016/j.biomaterials.2018.08.062

M3 - Article

C2 - 30336364

AN - SCOPUS:85054816743

VL - 187

SP - 117

EP - 129

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -